The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. This decision was taken November 20 by the EU’s 27 member states in the margins of the General Affairs Council (Article 50). The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on March 30, 2019 at the latest.
“We welcome today’s decision on the new location of EMA. Now that we finally know where our journey is taking us, we can take concrete actions for a successful move,” said EMA Executive Director Guido Rasi.
“Amsterdam ticks many of our boxes,” he continued. “It offers excellent connectivity and a building that can be shaped according to our needs. I am very grateful that the Member States took into account our requirements for business continuity and gave priority to the protection of public and animal health.
Our internal surveys have shown that a large majority of EMA staff would be willing to move with the agency to Amsterdam. However even in this case, our activities will be impacted and we need to plan for this now to avoid the creation of gaps in knowledge and expertise.”
EMA has been based in London, UK, since it was established in 1995. It currently employs nearly 900 staff members at its headquarters in Canary Wharf, London.
The relocation of EMA from London is a consequence of the UK’s withdrawal from the European Union. The Agency was not involved in the selection of the new location.
EMA has to relocate due to the United Kingdom’s decision to withdraw from the EU. Amsterdam was one of 19 offers to host EMA submitted by the member states at the end of July 2017. Monday’s decision on EMA’s new location follows an assessment of the bids by the European Commission and EMA.
“My staff and I are very honored that so many member states showed an interest in hosting EMA,” Rasi commented. “The huge effort invested by the bidding countries to put together their proposals is a reflection of the agency’s important role in the protection of public and animal health and the stimulation of a vibrant and innovative pharmaceutical industry.”
The decision marks the official start of a challenging joint relocation project that will have to be delivered within extremely tight timelines whereby the relocation has to be completed by March 30, 2019.
Effective collaboration between the EMA and the Netherlands on the basis of the commitments made in its offer to host EMA is essential to ensure a successful move and the continuation of EMA’s operations with minimal disruption.
The EMA and the Netherlands will kick start their collaboration by establishing a joint governance structure to steer and oversee the relocation project. Because of its important role to safeguard public and animal health in the EU, EMA said is committed to giving stakeholders and the public full visibility of the relocation project.
In early December, the agency will make available a monitoring chart on its website that will allow interested parties to track the progress made.
(Source: European Medicines Agency)
